WO2004091524A3 - Respiratory virus vaccines - Google Patents

Respiratory virus vaccines Download PDF

Info

Publication number
WO2004091524A3
WO2004091524A3 PCT/US2004/011425 US2004011425W WO2004091524A3 WO 2004091524 A3 WO2004091524 A3 WO 2004091524A3 US 2004011425 W US2004011425 W US 2004011425W WO 2004091524 A3 WO2004091524 A3 WO 2004091524A3
Authority
WO
WIPO (PCT)
Prior art keywords
respiratory virus
virus vaccines
vaccines
respiratory
treating
Prior art date
Application number
PCT/US2004/011425
Other languages
French (fr)
Other versions
WO2004091524A2 (en
Inventor
Thomas P Monath
Harold Kleanthous
Original Assignee
Acambis Inc
Thomas P Monath
Harold Kleanthous
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Acambis Inc, Thomas P Monath, Harold Kleanthous filed Critical Acambis Inc
Publication of WO2004091524A2 publication Critical patent/WO2004091524A2/en
Publication of WO2004091524A3 publication Critical patent/WO2004091524A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Abstract

The invention provides vaccines and methods for preventing, treating, and diagnosing respiratory virus infection.
PCT/US2004/011425 2003-04-14 2004-04-14 Respiratory virus vaccines WO2004091524A2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US46299503P 2003-04-14 2003-04-14
US60/462,995 2003-04-14
US51501003P 2003-10-28 2003-10-28
US60/515,010 2003-10-28

Publications (2)

Publication Number Publication Date
WO2004091524A2 WO2004091524A2 (en) 2004-10-28
WO2004091524A3 true WO2004091524A3 (en) 2009-04-16

Family

ID=33303110

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2004/011425 WO2004091524A2 (en) 2003-04-14 2004-04-14 Respiratory virus vaccines

Country Status (1)

Country Link
WO (1) WO2004091524A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110974950A (en) * 2020-03-05 2020-04-10 广州恩宝生物医药科技有限公司 Adenovirus vector vaccine for preventing SARS-CoV-2 infection

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2529736T3 (en) * 2003-04-10 2015-02-25 Novartis Vaccines And Diagnostics, Inc. Immunogenic composition comprising a SARS coronavirus spicular protein
US8080642B2 (en) 2003-05-16 2011-12-20 Vical Incorporated Severe acute respiratory syndrome DNA compositions and methods of use
WO2006071250A2 (en) * 2004-04-05 2006-07-06 Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Soluble fragments of the sars-cov spike glycoprotein
TWI293957B (en) 2004-07-21 2008-03-01 Healthbanks Biotech Co Ltd A superantigen fusion protein and the use thereof
WO2006095180A2 (en) * 2005-03-10 2006-09-14 Ultra Biotech Limited Humananized monoclonal antibodies against sars - associated coronavirus and treatment of patients with sars
CN1327900C (en) * 2005-03-30 2007-07-25 武汉大学 Attenuated typhoid bacillus vaccine of virus gene carried on chromosome and its preparation method
EP1736539A1 (en) * 2005-06-24 2006-12-27 Consejo Superior De Investigaciones Cientificas Attenuated SARS-CoV vaccines
EP1749833A1 (en) * 2005-08-05 2007-02-07 Healthbanks Biotech Co., Ltd. Super-antigens derived from the SARS coronavirus E2 spike protein
CN101020055B (en) * 2006-02-16 2012-08-08 中国疾病预防控制中心性病艾滋病预防控制中心 SARS vaccine based on replicative vaccinia virus vector
GB0711858D0 (en) * 2007-06-19 2007-07-25 Glaxosmithkline Biolog Sa Vaccine
WO2021147025A1 (en) * 2020-01-22 2021-07-29 The University Of Hong Kong-Shenzhen Hospital Anti 2019-ncov vaccine
US20220347289A1 (en) * 2020-02-23 2022-11-03 Guangzhou N Biomed Ltd. Nucleotide sequences encoding peptide antigens of sars-cov-2 virus and use thereof
KR20210147875A (en) * 2020-05-29 2021-12-07 경성대학교 산학협력단 Composition for preventing or treating sars coronavirus 2 infection disease
WO2023003911A2 (en) * 2021-07-19 2023-01-26 Loma Linda University Mucosal vaccines for coronavirus diseases

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
BACA-ESTRADA ME ET AL.: "Tnduction of roucosal immunity in cotton rats to haemagglutinin- esterase glycoprotein of bovine coronavirus by recombinant adenovirus", IMMUNOLOGY., vol. 86, no. 1, 1995, pages 134 - 40 *
SAIF L.: "Coronavirus immunogens", VETERINARY MICROBIOLOGY, vol. 37, 1993, pages 285 - 297, XP023914319, DOI: doi:10.1016/0378-1135(93)90030-B *
TORRES, JM ET AL.: "Tropism of human adenovirus type 5-based vectors in swine and their ability to protect against transmissible gastroenteritis coronavirus", J. VIROL., vol. 70, 1996, pages 3770 - 3780, XP000616232 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110974950A (en) * 2020-03-05 2020-04-10 广州恩宝生物医药科技有限公司 Adenovirus vector vaccine for preventing SARS-CoV-2 infection
CN110974950B (en) * 2020-03-05 2020-08-07 广州恩宝生物医药科技有限公司 Adenovirus vector vaccine for preventing SARS-CoV-2 infection

Also Published As

Publication number Publication date
WO2004091524A2 (en) 2004-10-28

Similar Documents

Publication Publication Date Title
WO2003101397A3 (en) Tetravalent dengue vaccines
WO2007030810A3 (en) Multiparameter whole blood monitor and method
WO2004091446A3 (en) Medical device delivery systems
AP2212A (en) Phosphonates, Monophosphonamidates, Bisphosphonamidates for the treatment of viral diseases.
WO2004028454A3 (en) 1, 3, 5-triazines for treatment of viral diseases
WO2004060308A3 (en) Thiosemicarbazones as anti-virals and immunopotentiators
WO2004069156A3 (en) Inactivated probiotic bacteria and methods of use thereof
DE602004024542D1 (en) SUB-VACCINE AGAINST THE RESPIRATORY SYNZYTIALVIRUS
AP2006003525A0 (en) Ä1,8ÜNapthyridin-2-ones and related compounds for the treatment of schizophrenia.
WO2007024705A3 (en) Method of treating depression using a tnf-alpha antibody
WO2004091524A3 (en) Respiratory virus vaccines
WO2006002437A3 (en) Treatment of conditions involving demyelination
HK1105281A1 (en) Hemorrhagic feline calicivirus, calicivirus vaccine and method for preventing calicivirus infection or disease
WO2004069184A3 (en) Methods for treating, preventing and detecting helicobacter infection
CL2004000799A1 (en) PREVENTION METHOD OF ABORTION IN PRESSED ANIMAL CAUSED BY AN HVB-1 VIRUS, AND / OR BY VDVB OR VDB VIRUS, INFECTION PREVENTION METHOD IN A INFANTING ANIMAL.
HUS1200029I1 (en) Avian e. coli vaccine for the protection against colibacillosis
EG23318A (en) Substituted aromatic amide derivative, intermediate thereof agrohorticultural insecticide containingthereof and method for the use thereof.
MXPA03007915A (en) Vaccine.
ZA200306232B (en) Treatment involving DKK-1 or antagonists thereof.
MXPA02012249A (en) Peptides, compositions and methods for the treatment of burkholderia cepacia.
WO2005000208A3 (en) Combination therapy for the treatment of neoplasms
ZA200306040B (en) Hepatitis B virus treatment.
EP1689347A4 (en) Methods and reagents for treating, preventing and diagnosing bunyavirus infection
EP1591069A4 (en) Surgical instrument, operation system, and anastomotic operation method using the surgical instrument
WO2006017857A3 (en) Antibiotic resistance free dna vaccines

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase